Cazzorla Chiara, Cegolon Luca, Burlina Alessandro P, Celato Andrea, Massa Pamela, Giordano Laura, Polo Giulia, Daniele Aurora, Salvatore Francesco, Burlina Alberto B
Division of Inborn Metabolic Diseases, Department of Pediatrics, Padua University Hospital, Padua, Italy.
BMC Public Health. 2014 Dec 4;14:1243. doi: 10.1186/1471-2458-14-1243.
Phenylketonuria (PKU) is a chronic inborn error of amino acid metabolism that requires lifelong follow-up and intervention, which may represent strains on Quality of Life (QoL). This observational study evaluated QoL in a cohort of PKU patients, using updated and detailed instruments.
22 patients with mild PKU respondent to BH4 and 21 patients with classical PKU treated with diet were recruited in this study. Adult patients completed WHOQOL questionnaire-100 (WHOQOL-100) and pediatric patients the Pediatric QoL inventory (PedsQL(TM)). Psychiatric and mood disorders were also evaluated using TAD or BDI and STAI-Y inventories. A multivariable linear regression model was fitted to investigate the predictors of QoL, including age, sex, treatment type, length of current treatment, educational level and employment status (only for adults) as covariates. Results were presented as regression coefficients with 95% confidence interval.
Global QoL scores were within normal range both in patients with mild and classical disease but global QoL scores were significantly higher in patients with mild PKU under BH4 treatment as compared to those affected by classical disease who were under diet regimen. Furthermore, QoL significantly increased in long treated PKU patients. Among adult patients, QoL scores were significantly lower in males, in patients with lower education and in those employed or unemployed as compared to students (baseline).
Both diet and medical treatment based upon BH4 seem to be associated with higher QoL in the long run. However, patients with mild PKU can rely on BH4 to achieve a higher Phe tolerance and a better compliance to therapy due to diet relaxation/avoidance. Some specific categories of patients with a lower QoL should be investigated more in depth, engaging with those at risk of lower treatment compliance. The questionnaires employed in the present study seemed to be able to effectively detect criticalities in QoL assessment and represent an advance from previous inventories employed in the past.
苯丙酮尿症(PKU)是一种慢性先天性氨基酸代谢紊乱疾病,需要终身随访和干预,这可能对生活质量(QoL)造成压力。本观察性研究使用更新且详细的工具评估了一组PKU患者的生活质量。
本研究招募了22名对四氢生物蝶呤(BH4)有反应的轻度PKU患者和21名接受饮食治疗的经典型PKU患者。成年患者完成了世界卫生组织生活质量问卷100(WHOQOL - 100),儿科患者完成了儿童生活质量量表(PedsQL™)。还使用TAD或BDI以及STAI - Y量表评估了精神和情绪障碍。拟合多变量线性回归模型以研究生活质量的预测因素,包括年龄、性别、治疗类型、当前治疗时长、教育水平和就业状况(仅针对成年人)作为协变量。结果以回归系数及95%置信区间呈现。
轻度和经典型疾病患者的总体生活质量得分均在正常范围内,但与接受饮食疗法的经典型疾病患者相比,接受BH4治疗的轻度PKU患者的总体生活质量得分显著更高。此外,长期接受治疗的PKU患者的生活质量显著提高。在成年患者中,与学生(基线)相比,男性、教育程度较低的患者以及就业或失业的患者的生活质量得分显著较低。
从长远来看,基于BH4的饮食和药物治疗似乎都与较高的生活质量相关。然而,轻度PKU患者可以依靠BH4来实现更高的苯丙氨酸耐受性,并由于饮食放宽/避免而更好地依从治疗。应更深入地研究一些生活质量较低的特定患者类别,关注那些治疗依从性较低风险的患者。本研究中使用的问卷似乎能够有效地检测生活质量评估中的关键问题,并且代表了相对于过去使用的以往量表的进步。